866-997-4948(US-Canada Toll Free)

B-Cell Leukemia - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 92 Pages


Global Markets Directs, \'B-Cell Leukemia Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Leukemia. 

B-Cell Leukemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for B-Cell Leukemia.
  • A review of the B-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the B-Cell Leukemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for B-Cell Leukemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding B-Cell Leukemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
B-Cell Leukemia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for B-Cell Leukemia 10
B-Cell Leukemia Therapeutics under Development by Companies 12
B-Cell Leukemia Therapeutics under Investigation by Universities/Institutes 15
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
B-Cell Leukemia Therapeutics - Products under Development by Companies 20
B-Cell Leukemia Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in B-Cell Leukemia Therapeutics Development 23
Bristol-Myers Squibb Company 23
Amgen Inc. 24
MedImmune LLC 25
Lentigen Corporation 26
Novartis AG 27
Glenmark Pharmaceuticals Ltd. 28
GTC Biotherapeutics, Inc. 29
Nippon Shinyaku Co., Ltd. 30
Ono Pharmaceutical Co., Ltd. 31
Mundipharma International Limited 32
Cancer Research Technology Limited 33
Celentyx Ltd. 34
Xencor, Inc. 35
SBI Biotech Co., Ltd. 36
Advancell 37
B-Cell Leukemia - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
moxetumomab pasudotox - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
acadesine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
bafetinib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
forodesine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BMS-936564 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
XmAb-5485 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
DI-B4 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CTL-019 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
navitoclax + [rituximab] - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
HGC-1 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Leukapheresis + Fludarabine + Cyclophosphamide + Autologous CD19 Specific T-cell Infusion - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
GNKG-168 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GBR-401 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
lenaldekar - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
TP-0829 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Bendamustine + Ofatumumab + Methylprednisolone - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ilorasertin + [azacitidine] - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
ONO-4059 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Anti-CD 19 CAR Autologous PBL - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
rituximab Biosimilar - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Allogeneic CD19CAR-TCM cells - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Bendamustine + [Alemtuzumab] - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Anti-APRIL - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
LG-740 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
B-Cell Leukemia Therapeutics - Drug Profile Updates 80
B-Cell Leukemia Therapeutics - Discontinued Products 84
B-Cell Leukemia Therapeutics - Dormant Products 85
B-Cell Leukemia - Product Development Milestones 87
Featured News & Press Releases 87
Nov 05, 2012: Emergent BioSolutions To Present Data On TRU-016 And Bendamustine Combination Therapy At ASH Annual Meeting 2012 87
Nov 05, 2012: Emergent BioSolutions To Present Phase Ib Data Of TRU-016 In Combination With Rituximab And Bendamustine At ASH Annual Meeting 2012 88
Aug 24, 2012: TG Therapeutics Announces Poster Presentation For Ublituximab At 7th International Workshop On Waldenstrom\'s Macroglobulinemia 89
Jun 04, 2007: ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial In B-Cell Chronic Lymphocytic Leukemia 90

Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92

List of Table


Number of Products Under Development for B-Cell Leukemia, H1 2013 10
Products under Development for B-Cell Leukemia - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
Bristol-Myers Squibb Company, H1 2013 23
Amgen Inc., H1 2013 24
MedImmune LLC, H1 2013 25
Lentigen Corporation, H1 2013 26
Novartis AG, H1 2013 27
Glenmark Pharmaceuticals Ltd., H1 2013 28
GTC Biotherapeutics, Inc., H1 2013 29
Nippon Shinyaku Co., Ltd., H1 2013 30
Ono Pharmaceutical Co., Ltd., H1 2013 31
Mundipharma International Limited, H1 2013 32
Cancer Research Technology Limited, H1 2013 33
Celentyx Ltd., H1 2013 34
Xencor, Inc., H1 2013 35
SBI Biotech Co., Ltd., H1 2013 36
Advancell, H1 2013 37
Assessment by Monotherapy Products, H1 2013 38
Assessment by Combination Products, H1 2013 39
Assessment by Stage and Route of Administration, H1 2013 41
Assessment by Stage and Molecule Type, H1 2013 43
B-Cell Leukemia Therapeutics - Drug Profile Updates 80
B-Cell Leukemia Therapeutics - Discontinued Products 84
B-Cell Leukemia Therapeutics - Dormant Products 85
B-Cell Leukemia Therapeutics - Dormant Products (Contd..1) 86

List of Chart


Number of Products under Development for B-Cell Leukemia, H1 2013 10
Products under Development for B-Cell Leukemia - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Discovery and Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 38
Assessment by Combination Products, H1 2013 39
Assessment by Route of Administration, H1 2013 40
Assessment by Stage and Route of Administration, H1 2013 41
Assessment by Molecule Type, H1 2013 42
Assessment by Stage and Molecule Type, H1 2013 43

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *